CJC-1295 + Egrifta (Tesamorelin) Stack: Evidence, Mechanism Overlap, and Protocol

What are CJC-1295 and tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing factor: the 44-amino-acid human sequence with a hexenoyl group on the N-terminal tyrosine, molecular weight about 5135.9 Da, and a peptide rather than growth hormone itself [1]. In vitro it binds and stimulates human GRF receptors with potency similar to the body's own GRF, and pituitary somatotroph cells respond by making and releasing more of the body's own GH, which raises IGF-1 and IGFBP-3 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both once-daily subcutaneous injections [1][2].

CJC-1295 is an investigational long-acting GHRH analogue developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [3][6]. FDA describes two forms: a 29-amino-acid GHRH analogue, and CJC-1295 DAC, which is the same peptide with an extra maleimidopropionic acid-lysine unit at the C-terminal end that lets it bind blood albumin and last much longer [3]. In the rat work that identified it, CJC-1295 produced about 4-fold greater GH exposure over 2 hours than native GHRH(1-29) and was still detectable in plasma beyond 72 hours [6].

Do they work through the same mechanism?

Yes, the overlap is at the receptor. Tesamorelin's label describes it binding and stimulating human GRF receptors on pituitary somatotroph cells [1], and CJC-1295 is a GHRH analogue acting on the same pituitary target, raising GH and, through GH, IGF-1 [4][7].

The kinetics are very different. After one subcutaneous injection of CJC-1295 DAC the estimated half-life was 5.8 to 8.1 days, mean plasma GH rose 2- to 10-fold for 6 days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days [4]. Tesamorelin's mean elimination half-life was 8 minutes with Egrifta SV and 11 minutes with Egrifta WR in healthy subjects [1][2].

Despite the long half-life of CJC-1295 DAC, GH pulsatility persisted. In healthy men given a single 60 or 90 micrograms/kg injection, GH pulse frequency and pulse size were unchanged a week later, while trough GH rose about 7.5-fold, mean GH 46% and IGF-I 45% [7].

What tesamorelin's trials actually show

Tesamorelin's evidence comes from two randomized, double-blind, placebo-controlled trials in HIV-infected adults with excess abdominal fat, each with a 26-week main phase and a 26-week extension [1].

Study 1 enrolled 412 patients given 2 mg daily or placebo. Visceral adipose tissue on CT fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL versus a rise of 9 mg/dL; the total-to-HDL cholesterol ratio fell 0.31 versus a rise of 0.21; and IGF-1 rose 81.0% versus a fall of 5.0% (P<0.001 for all) [8].

Study 2 randomized 404 patients 2:1. At 6 months visceral fat fell 10.9% (−21 cm2) versus 0.6% (−1 cm2) on placebo (P<0.0001) [9]. In the pooled phase 3 analysis of 806 patients (543 tesamorelin, 263 placebo), week-26 visceral fat changed −24 versus +2 cm2, a treatment effect of −15.4%, and triglycerides −37 versus +6 mg/dL [10].

In the extension, visceral fat did not stay down once treatment stopped. From week 26 to week 52, visceral fat changed 0% and −5% in the two studies among patients who stayed on tesamorelin, versus +22% and +16% among those switched to placebo [1]. The label states that long-term cardiovascular safety has not been established and that tesamorelin is not indicated for weight loss management because its effect on weight is neutral [1]. The approved use is narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1].

What CJC-1295's human data show

Far less. FDA identified only three published human studies of CJC-1295, all of the DAC form and all in healthy volunteers (Teichman 2006, Ionescu and Frohman 2006, Sackmann-Sala 2009), and found no study of any form in people with a disease [3].

Teichman 2006 was two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61, using single doses in the first study and two or three weekly or biweekly doses in the second; FDA counted 35 treated subjects and 7 on placebo in the first study [4][3]. The main outcomes were GH and IGF-1 concentrations and drug pharmacokinetics, not fat mass, body composition or any clinical endpoint [4].

According to FDA's briefing, ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. The data were never published, so a causal link is neither shown nor excluded [3]. FDA's compounding page also lists serious adverse events it associates with CJC-1295, including increased heart rate and systemic vasodilatory reaction, and describes the available clinical data as limited [11].

What doses do the labels and the CJC-1295 studies use?

There is no FDA-approved dose of CJC-1295 at all [3]. The doses used in the human studies were single subcutaneous injections of about 30 to 250 micrograms/kg, or two to three doses given weekly or every two weeks, and those were study doses rather than recommendations [3][4].

The current tesamorelin labels specify different once-daily doses: Egrifta SV is 1.4 mg and Egrifta WR is 1.28 mg; the labels say the products are not substitutable and differ in diluent, reconstitution, storage and vial use [1][2]. The 2 mg daily dose used in the trials was the original 1 mg/vial product; FDA accepted the 1.4 mg SV dose because its exposure is similar [1].

Risk considerations for combining them

Both peptides can raise GH and IGF-1. The tesamorelin label and FDA's summary of CJC-1295 each describe their own risks; neither describes the combination [1][3].

The tesamorelin label warns about increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions and injection-site reactions. The label says tesamorelin is contraindicated in people with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy [1][2]. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated 52 weeks, 34% and 23%; the label asks prescribers to consider stopping for persistent elevations such as above 3 SDS, particularly if the fat-loss response is not robust [1]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1]. Injection-site reactions occurred in 25% versus 14% during the first 26 weeks, and the most common reactions overall were arthralgia (13% versus 11%), peripheral edema (6% versus 2%) and myalgia (6% versus 2%) [1]. Hypersensitivity reactions occurred in 4% of treated patients, with itching, redness, flushing, hives and rash [1].

For CJC-1295, the two Teichman trials reported injection-site reactions in about 70% of treated subjects in study 1 and in all treated subjects in study 2, headache in 63% versus 14% on placebo in study 1, and flushing, warmth and transient low blood pressure in about 30% of treated subjects in study 1, with no serious adverse reactions reported [3][4]. In Ionescu and Frohman 2006 (healthy men, one dose of 60 or 90 micrograms/kg), no serious adverse events were seen, but heart rate rose with dose and injection sites showed transient redness and tenderness [3]. FDA's stated position is that GH and IGF-I elevation carries the risks listed on approved growth hormone labels, such as glucose intolerance and diabetes, fluid retention and tumor growth concerns, and that the CJC-1295 studies were short, small and mostly single-dose, so long-term safety is unknown [3].

Tesamorelin's label flags possible interactions with glucocorticoid replacement and with drugs cleared by CYP450 enzymes [1].

Regulatory status of each

Tesamorelin is an FDA-approved prescription drug, first approved on November 10, 2010, and it is not on FDA's list of bulk substances that may present significant safety risks, nor in any category of FDA's lists for state-licensed pharmacies or outsourcing facilities [12][11][13][14]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [15].

CJC-1295 is not FDA-approved. FDA found no approved product containing it in the countries it searched and none authorized by the European Medicines Agency [3]. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [16]. It sits in the nominated-but-withdrawn table of FDA's safety-risk page, having been in category 2 until the nominators withdrew, and it is in no category of FDA's list for state-licensed pharmacies and physicians, so FDA's category 1 policy does not apply to it [11][13]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [17]. Most CJC-1295 sold online is labeled research use only, including blends with ipamorelin, and it has been found in illicit sports use [3].

For athletes, both compounds are named in the WADA Prohibited List under S2.2.4 as growth hormone-releasing factor analogues, prohibited at all times, in and out of competition [5][18].